Upadacitinib (anti-JAK1), fedratinib (anti-JAK2), and oclacitinib (anti-JAK1) were approved by FDA for rheumatoid arthritis, myelofibrosis, and dermatitis, respectively [42]. This evidence concerns the gene JAK1 and skin disorder.